登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
ClinicalTrials.gov 上登记的一项胰腺癌开放试验。牵头方不是本站收录的医院;本站收录的 8 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 8
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
- 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
- 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
- 研究中心湖南省人民医院(湖南师范大学附属第一医院)Hunan Provincial People's Hospital长沙医院页面
- 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
- 研究中心上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面
- 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
- 研究中心浙江省人民医院Zhejiang Provincial People's Hospital杭州医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT05911217,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 79 岁;性别:不限
登记记录的入选字段
Histologically confirmed pancreatic ductal adenocarcinoma;
入选标准第 3 条
Postoperative pathological stage (pTNM): T1-3, N0-2, M0;
入选标准第 5 条
ECOG performance status score 0-1;
入选标准第 10 条
Positive serology for HIV, Treponema pallidum or HCV;
排除标准第 8 条
Subjects who have other uncured malignant tumors in the past 3 years or at the same time, except those with very low degree of malignancy such as cervical cancer in situ and basal cell carcinoma of skin;
排除标准第 22 条
Men and women of childbearing potential must be willing to use effective methods of contraception to prevent pregnancy;
入选标准第 12 条
Pregnant or lactating women;
排除标准第 7 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05911217,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntary participation in the clinical trial; fully understand, be informed about this study and have signed the ICF; willing to follow and able to complete all study procedures; Aged 18 to 79 years; Histologically confirmed pancreatic ductal adenocarcinoma; Macroscopic complete tumor removal ; Postoperative pathological stage (pTNM): T1-3, N0-2, M0; Immunohistochemistry (IHC) staining of subject's tumor tissue sample is CLDN18.2-positive; Subjects had recovered from surgery and had received months of standard adjuvant therapy; Abnormal of Specific tumor marker level; With sufficient venous access for leukapheresis collection; ECOG performance status score 0-1; Adequate organ function; Men and women of childbearing potential must be willing to use effective methods of contraception to prevent pregnancy;排除标准:Exclusion Criteria:
Prior neoadjuvant therapy for pancreatic cancer; Subjects with borderline resectable pancreatic cancer; Present or past history of metastatic or locally recurrent pancreatic cancer; Evidence of malignant ascites; Subjects had diseases that may interfere with CA19-9 level. Toxicities caused by previous treatment have not recovered to CTCAE ≤ grade 2, except alopecia and other tolerable events as judged by the investigator or laboratory abnormalities allowed in this study; Pregnant or lactating women; Positive serology for HIV, Treponema pallidum or HCV; Any active infections; Clinically significant thyroid dysfunction; Previous allergy to immunotherapy and related drugs, allergy to CT041 ingredients and other serious allergic history; Subjects who may be at high risk for potential digestive tract bleeding or perforation; Known active autoimmune disease, including but not limited to, psoriasis or rheumatoid arthritis, or other conditions requiring long-term immunosuppressive therapy; Subjects who have a history of organ transplantation or are awaiting organ transplantation; Subjects who require anticoagulant therapy; Subjects who are receiving or are expected to require long-term antiplatelet therapy during the study; Subjects who have experienced major surgery or have significant trauma within 4 weeks before apheresis, or who are expected to undergo major surgery during the study period; Previously received any gene-modified cell therapies (including CAR T, TCR T); Subjects who have other serious diseases that may restrict them from participating in the study assessed by investigators; Subjects with oxygen saturation ≤ 95%; Subjects who have signs of central nervous system diseases or clinically significant neurological examination abnormalities; Subjects who have other uncured malignant tumors in the past 3 years or at the same time, except those with very low degree of malignancy such as cervical cancer in situ and basal cell carcinoma of skin; Vaccination with live attenuated vaccines within 4 weeks prior to apheresis or planned during the study; Subjects who are unable to or unwilling to comply with the requirements of the study protocol as assessed by investigators.
引自 ClinicalTrials.gov, NCT05911217, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05911217,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。